184 related articles for article (PubMed ID: 20436502)
1. Pathology of hereditary breast cancer.
Da Silva L; Lakhani SR
Mod Pathol; 2010 May; 23 Suppl 2():S46-51. PubMed ID: 20436502
[TBL] [Abstract][Full Text] [Related]
2. Histopathological features of 'BRCAX' familial breast cancers in the kConFab resource.
Loughrey M; Provan PJ; Byth K; ; Balleine RL
Pathology; 2008 Jun; 40(4):352-8. PubMed ID: 18446624
[TBL] [Abstract][Full Text] [Related]
3. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
4. [Hereditary breast carcinomas pathologist's perspective].
Vincent-Salomon A; Bataillon G; Djerroudi L
Ann Pathol; 2020 Apr; 40(2):78-84. PubMed ID: 32241645
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG
Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863
[TBL] [Abstract][Full Text] [Related]
6. p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.
Sensi E; Tancredi M; Aretini P; Cipollini G; Naccarato AG; Viacava P; Bevilacqua G; Caligo MA
Breast Cancer Res Treat; 2003 Nov; 82(1):1-9. PubMed ID: 14672397
[TBL] [Abstract][Full Text] [Related]
7. Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeutics.
Rubinstein WS
Fam Cancer; 2008; 7(1):83-9. PubMed ID: 17624601
[TBL] [Abstract][Full Text] [Related]
8. The pathology of inherited breast cancer.
Armes JE; Venter DJ
Pathology; 2002 Aug; 34(4):309-14. PubMed ID: 12190286
[TBL] [Abstract][Full Text] [Related]
9. Analysis of BRCA1/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing.
Li G; Guo X; Tang L; Chen M; Luo X; Peng L; Xu X; Wang S; Xiao Z; Yi W; Dai L; Wang J
J Cancer Res Clin Oncol; 2017 Oct; 143(10):2011-2024. PubMed ID: 28664449
[TBL] [Abstract][Full Text] [Related]
10. BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness.
Domagala P; Hybiak J; Cybulski C; Lubinski J
Int J Cancer; 2017 Apr; 140(7):1545-1550. PubMed ID: 27943282
[TBL] [Abstract][Full Text] [Related]
11. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
[TBL] [Abstract][Full Text] [Related]
12. The "portrait" of hereditary breast cancer.
Lacroix M; Leclercq G
Breast Cancer Res Treat; 2005 Feb; 89(3):297-304. PubMed ID: 15754129
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers.
Domagala P; Jakubowska A; Jaworska-Bieniek K; Kaczmarek K; Durda K; Kurlapska A; Cybulski C; Lubinski J
PLoS One; 2015; 10(6):e0130393. PubMed ID: 26083025
[TBL] [Abstract][Full Text] [Related]
14. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
15. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
[TBL] [Abstract][Full Text] [Related]
16. Hereditary breast cancer: from molecular pathology to tailored therapies.
Tan DS; Marchiò C; Reis-Filho JS
J Clin Pathol; 2008 Oct; 61(10):1073-82. PubMed ID: 18682420
[TBL] [Abstract][Full Text] [Related]
17. Identification of germline BRCA1 and BRCA2 genetic alterations in Greek breast cancer moderate-risk and low-risk individuals--correlation with clinicopathological data.
Kataki A; Gomatos I; Pararas N; Armakolas A; Panousopoulos D; Karantzikos G; Voros D; Zografos G; Markopoulos C; Leandros E; Konstadoulakis M
Clin Genet; 2005 Apr; 67(4):322-9. PubMed ID: 15733268
[TBL] [Abstract][Full Text] [Related]
18. Targeted sequencing to discover germline variants in the BRCA1 and BRCA2 genes in a Russian population and their association with breast cancer risk.
Solodskikh SA; Panevina AV; Gryaznova MV; Gureev AP; Serzhantova OV; Mikhailov AA; Maslov AY; Popov VN
Mutat Res; 2019 Jan; 813():51-57. PubMed ID: 30611917
[TBL] [Abstract][Full Text] [Related]
19. BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers.
Vos S; Moelans CB; van Diest PJ
Breast Cancer Res; 2017 May; 19(1):64. PubMed ID: 28569220
[TBL] [Abstract][Full Text] [Related]
20. Childhood cancer in families with and without BRCA1 or BRCA2 mutations ascertained at a high-risk breast cancer clinic.
Brooks GA; Stopfer JE; Erlichman J; Davidson R; Nathanson KL; Domchek SM
Cancer Biol Ther; 2006 Sep; 5(9):1098-102. PubMed ID: 16931905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]